PERSPEKTIVY PRIMENENIYa S-1 V LEChENII BOL'NYKh RAKOM ZhELUDKA
- Autores: Lud A.N1, Abramov M.E1, Meshcheryakov A.A1
-
Afiliações:
- Edição: Nº 10 (2014)
- Páginas: 75-78
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287063
- ID: 287063
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The appearance of S-1 - peroral fluorinated pyrimidine - has allowed to take a new look at the treatment of patients with metastatic stomach cancer. The combination of S-1 with cisplatin has provided improvement in overall survival against the background of absence of clinically significant toxicity. The use of S-1 as monotherapy for adjuvant purposes has led to the significant increase in the three-year disease-free survival of patients with stomach cancer (72.2 vs 60.1 %, P < 0.0001). Great interest to the S-1 was confirmed by numerous ongoing international studies which have evaluated the effectiveness of S-1 not only in combination with other cytotoxic drugs, but also with targeted drugs.
Texto integral
Bibliografia
- Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215-21. Epub 2008.
- Jin M., Lu H., Li J., et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S- 1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastriccancer (AGC): SC-101 study. J. Clin. Oncol. (Meeting Abstracts) 2008; 26(15): suppl 4533.
- Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007; 357: 1810-20. ся метастазы до 0,3 см в диаметре, в брюшной полости и забрюшинном пространстве определяются увеличенные лимфатические узлы до 1,0 см в диаметре. Достигнутый эф-
- Ajani J.A., Rodgriguez W., Bodoky G., et al. Multicenter Phase 3 comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). Presented at the American Society of Clinical Oncology: 2009 Gastrointestinal Cancers Symposium (abstr 8).
- Ajani J.A., Rodgriguez W., Bodoky G., et al. Multicenter Phase 3 comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J. Clin. Oncol. 2009; 27: 15s (abstr 4511).
- Ajani J.A., Rodriguez W., Bodoky G., et al. Multicenter phase III comparison of cisplatin/S-1 фект сохранялся в течение всего периода лечения. Таким образом, длительность химиотерапии первой линии с включением S-1 составила 91 месяц. with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 2010; 28: 1547-53.
- Koizumi W., Kim Y.H., Fujii M., et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J. Cancer Res. Clin. Oncol. 2014: 140(2): 319-28.
- Narahara H., Iishi H., Imamura H., et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011; 14(1): 72-80.
Arquivos suplementares
